← Back to Search

PSMA-PET Imaging for Prostate Cancer

Phase 3

Recruiting

Led By Daniel Juneau, MD

Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 10 years

Awards & highlights

Study Summary

This trial is investigating whether a new imaging technique, PSMA-PET, can help guide treatment and find predictive imaging biomarkers through deep learning techniques in men with prostate cancer.

Who is the study for?

This trial is for men with prostate cancer who are being treated at CHUM and have been recommended by their doctor to get a PSMA-PET scan. It's not suitable for those who can't undergo imaging procedures due to claustrophobia or other reasons.Check my eligibility

What is being tested?

The study tests the use of a new PET probe called [18F]DCFPyL IV injection in detecting metastases in prostate cancer patients. It aims to combine this advanced imaging technique with deep learning to find predictive biomarkers.See study design

What are the potential side effects?

As the intervention involves an imaging procedure, potential side effects may include discomfort from lying still during the scan and reactions to the tracer like mild rash or nausea, though serious side effects are rare.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 10 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~10 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Overall survival

Secondary outcome measures

Progression free survival

Trial Design

1Treatment groups

Experimental Treatment

Group I: Main armExperimental Treatment1 Intervention

PET-CT imaging following 18F-DCFPyL injection, 1 injection, IV, 10 mCi

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor

366 Previous Clinical Trials

128,637 Total Patients Enrolled

4 Trials studying Prostate Cancer

1,109 Patients Enrolled for Prostate Cancer

Daniel Juneau, MDPrincipal InvestigatorCentre hospitalier de l'Université de Montréal (CHUM)

2 Previous Clinical Trials

20,500 Total Patients Enrolled

Media Library

18F-DCFPyL IV injection Clinical Trial Eligibility Overview. Trial Name: NCT03594760 — Phase 3

Prostate Cancer Research Study Groups: Main arm

Prostate Cancer Clinical Trial 2023: 18F-DCFPyL IV injection Highlights & Side Effects. Trial Name: NCT03594760 — Phase 3

18F-DCFPyL IV injection 2023 Treatment Timeline for Medical Study. Trial Name: NCT03594760 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can new participants still join this experiment?

"The trial, which was first posted on December 1st, 2018, is still recruiting patients, as of August 5th, 2022."

Answered by AI

How many people suffering from this disease will be given the chance to try this new treatment?

"Yes, the clinicaltrials.gov website indicates that this research is still looking for participants. The trial was first posted on December 1st, 2018 and was last updated on August 5th, 2022. They are hoping to enroll 1000 people total from 1 research site."

Answered by AI